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Identifying the Problem
• Approximately 1.2 million people are at high risk of contracting HIV in the 
United States
• Daily PrEP (Truvada) use can lower HIV contraction through anal sex by 
90% and through IV drug use by 70% 
• As of 2016 only 77,000 people were prescribed PrEP, a 73% increase from 
2012
• 93% were men
• 64% were between 25-44 years old
• The rate of PrEP use is 2 times higher in the northeast than the rest of the 
country, with a majority of those users in New York
• Vermont is aiming to have zero new transmission by 2020, and PrEP will be 
important to reaching that goal
Barriers to prescribing PrEP in 
Vermont
Survey completed in 2015 by the Larner College Medicine 
found:
• 52% of providers in Vermont felt training was a barrier
• Long term safety of use and drug resistance were 
significant concerns
• 47% of providers considered themselves “not confident 
at all” when asked about having an informed discussion 
about PrEP with patients
As of 2016:
• 671 persons are living with HIV/AIDS in Vermont
• Of these 69% were residents of Vermont at time of their 
diagnosis
• Over 1/3 of persons diagnosed with HIV/AIDS in Vermont live 
in Chittenden County
There were 8 new HIV diagnoses in Vermont in 2016
Public Health Cost
• The total lifetime treatment cost in the United 
States for HIV infection based on diagnosis in 
2009 was estimated to be $16.6 billion
• Vermont’s total lifetime treatment cost based 
on diagnosis in 2009 was $4 million
• $379,668 lifetime cost per person diagnosed in 2009 
with HIV
• Farnham et al. study estimated the medical 
savings from prevention programs between 
1991-2006 to be $129.9 billion 
• 361,878 infections prevented
• Cash paying customers pay $1,758 for 30 
tablets of Truvada, although most insurance 
plans cover the cost.
Community Perspective
“If we truly want to get to our goal of zero new transmissions by 2020 
we need to have a holistic approach, looking at prevention and 
medications like PrEP”
• Taylor Small , Director of Health and Wellness at the Pride Center of Vermont
“I do feel we could use more sexual health and HIV prevention and 
treatment in our residency. I am usually very upfront with my patients 
to let them know that I may need to take some time to reference and 
find more information for them, but that I am happy to do so as part of 
my own learning, but also to take care of their needs.”
• Kelly Brooks, MD Chief Resident University of Vermont Family Medicine Residency
Intervention and Methodology
• An educational card was distributed to the 
residents and attending physicians at a local 
family medicine practice, inviting them to use the 
information as a resource for prescribing and 
monitoring patients on PrEP
• A copy of the card was placed in the teaching 
area allowing easy access for providers
• The information card covered 
indications/contraindications, side effects, and 
necessary monitoring for patients on the 
medication
• Recommendations from the CDC, reference 
databases, and local LGBT+ outreach centers 
were incorporated into the educational card
Results/Response
• Conversation with Providers who have received and reviewed the 
information card felt the information would be helpful in their future 
discussion with patients looking to use PrEP
• Effectiveness of the Information card will best be measured by 
looking at the number of providers at the clinic that start prescribing 
PrEP, and the overall number of patients that are prescribed PrEP
• Future results will also be shown by surveying the providers about 
their confidence in prescribing PrEP after having time to utilize the 
information on the card
Evaluation of Effectiveness/response
• The effectiveness of the intervention would be evaluated by surveying 
providers at the clinic to determine their confidence level with 
prescribing and monitoring patients on PrEP, and by evaluating how 
helpful they perceived the flyer to be
• The effectiveness would also be gauged evaluation of patient charts, 
seeing if there was an increased frequency of discussion and 
prescription of PrEP after the implementation of the flyer
Recommendations for future projects
• Talking with the Family Medicine Residents, there is a lack of formal 
training in recognizing patients who would benefit from PrEP and how 
to initiate that conversation with patients.
• Future projects could create a formal training for residents, including 
simulation to help broach the topic with patients
• Looking to see what barriers patients have initiating the discussion of 
PrEP with their providers
• Future projects could evaluate how effective educational flyers are 
long term, and if the information is continually referenced and 
updated
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